| 生物活性 |
Danvatirsen (AZD9150) is an antisense oligonucleotide targeting STAT3 that reduces the viability of leukemia cell lines and promotes their apoptosis (Apoptosis), inhibits the expression of endogenous STAT3 and its downstream target genes, decreases the proliferative capacity and tumorigenicity of neuroblastoma and lymphoma cells, suppresses tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer, achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma, and can be used for research related to lymphoma, myelodysplastic syndromes, acute myeloid leukemia, neuroblastoma, and non-small cell lung cancer. |
体外研究 (In Vitro) |
Danvatirsen (2.5-10 μM) 可显著降低 KG1a、CMK、MOLM13 和 KT1 白血病细胞系中的 STAT3 mRNA 水平。 Danvatirsen (1-10 μM; 24-72 h) 可显著降低 NB4、MOLM14、MDS-L、MV411、KG1a、MOLM13、KT1 和 CMK 白血病/骨髓增生异常综合征 (MDS) 细胞系的活力。 Danvatirsen (5 μM (CMK), 10 μM (KT1, U937); 48 h) 可显著提高 CMK、KT1 和 U937 白血病细胞系的细胞凋亡水平。 Danvatirsen (2.5-10 μM; 24 h) 可显著降低原发性 MDS/AML 干细胞中的 STAT3 mRNA 水平。 Danvatirsen (10 μM; 14 days) 可增强原发性骨髓增生异常综合征 (MDS) 干/祖细胞的红系和髓系分化。 Danvatirsen (10 μM; 24 h) 可在 CMK 白血病细胞中在 mRNA 水平下调 STAT3 及其下游致癌靶基因 (IL1RAP、MSI2、MCL1、IL8、CXCR2),下调 CMK 白血病细胞中 STAT3、磷酸化 STAT3 以及 MCL1 的蛋白水平。 Danvatirsen 可在原代 TP53 突变型 MDS/AML 干/祖细胞中诱导剂量依赖性凋亡,降低集落实验中原代 AML 干细胞和祖细胞的再接种效率。 Danvatirsen (0.25-10 μM; 6 days) 可剂量依赖性地抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中 STAT3 mRNA 的表达,IC50 值分别为 0.69、0.64 和 0.76 μM。 Danvatirsen (0.25-10 μM; 6 days) 可剂量依赖性地抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中总 STAT3 蛋白及磷酸化 STAT3 蛋白的表达,IC50 值分别为 0.99 μM、0.97 μM 和 0.98 μM。 Danvatirsen (1 μM; 6 days) 可显著降低 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中多个 STAT3 靶基因的 mRNA 和蛋白表达水平。 Danvatirsen (1 μM; 4 weeks) 可显著抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞的增殖,在持续孵育过程中分别使细胞汇合度降低最高达 38%、37% 和 34%,抑制细胞的锚定非依赖性集落形成,使集落数量分别减少 20%、43% 和 67%。 Danvatirsen (1 μM; 6 days) 可显著增强 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞对 Cisplatin (MS-E94993) 的敏感性,使Cisplatin 的 IC50 值降低最多 2 倍,并可减弱 Cisplatin 诱导的 DNA 损伤应答通路激活。 Danvatirsen (0.005-5 μM; 5 days) 可通过自由摄取方式剂量依赖性地抑制 STAT3 依赖性人淋巴瘤细胞系 KARPAS299 和 SUP-M2 的增殖。
Cell Viability Assay
| Cell Line: |
NB4, MOLM14, MDS-L, MV411, KG1a, MOLM13, KT1, CMK leukemic/MDS cell lines |
| Concentration: |
10 μM |
| Incubation Time: |
24 h, 48 h, 72 h |
| Result: |
Induced a significant, dose-dependent decrease in cell viability across all tested cell lines. Showed greater inhibition at higher concentrations. |
Apoptosis Analysis
| Cell Line: |
CMK, KT1, U937 leukemic cell lines |
| Concentration: |
5 μM (CMK cells); 10 μM (KT1 and U937 cells) |
| Incubation Time: |
48 h |
| Result: |
Induced a significant increase in early apoptotic, late apoptotic, and necrotic cell populations compared with controls. Showed a dose-dependent effect observed across tested concentrations. |
Real Time qPCR
| Cell Line: |
CMK leukemic cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Downregulated expression of STAT3 and oncogenic/stem cell-associated genes including IL1RAP, MSI2, MCL1, IL8, and CXCR2 at the mRNA level. |
Western Blot Analysis
| Cell Line: |
CMK leukemic cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced STAT3 protein, phospho-STAT3, and MCL1 protein levels. |
Real Time qPCR
| Cell Line: |
SK-N-AS, NGP, IMR32 human neuroblastoma cell lines |
| Concentration: |
0.25-10 μM |
| Incubation Time: |
6 days |
| Result: |
Inhibited STAT3 mRNA levels in a dose-dependent manner. Achieved IC50 values of 0.69 μM in SK-N-AS cells, 0.64 μM in NGP cells, and 0.76 μM in IMR32 cells. |
Western Blot Analysis
| Cell Line: |
SK-N-AS, NGP, IMR32 human neuroblastoma cell lines |
| Concentration: |
0.25-10 μM |
| Incubation Time: |
6 days |
| Result: |
Decreased both total and phosphorylated STAT3 (Ser727, Tyr705) protein levels in a dose-dependent manner. Achieved IC50 values of 0.99 μM in SK-N-AS cells, 0.97 μM in NGP cells, and 0.98 μM in IMR32 cells. |
Cell Proliferation Assay
| Cell Line: |
SK-N-AS, NGP, IMR32 human neuroblastoma cell lines |
| Concentration: |
1 μM |
| Incubation Time: |
continuous incubation (up to 240 hours) |
| Result: |
Caused a significant decrease in cell growth: up to 38% decrease in SK-N-AS cells, up to 37% decrease in NGP cells, and up to 34% decrease in IMR32 cells. |
Cell Viability Assay
| Cell Line: |
SK-N-AS, NGP, IMR32 human neuroblastoma cell lines |
| Concentration: |
1 μM |
| Incubation Time: |
3 days pre-incubation, followed by 3 days co-incubation with cisplatin |
| Result: |
Significantly increased cisplatin sensitivity, resulting in a 2-fold decrease in cisplatin IC50 in NGP cells and IMR32 cells, and a smaller decrease in SK-N-AS cells. Attenuated cisplatin-induced activation of the ATM and ATR DNA damage response pathways, as shown by reduced phosphorylation of ATM, Chk2, ATR, Chk1, and γH2AX. |
Cell Proliferation Assay
| Cell Line: |
KARPAS299, SUP-M2 (human lymphoma cell lines) |
| Concentration: |
0.005-5 μM |
| Incubation Time: |
5 days |
| Result: |
Induced dose-dependent inhibition of cell proliferation in KARPAS299 and SUP-M2 cells. Showed antiproliferative effects that correlated with the degree of STAT3 depletion. |
|
体内研究 (In Vivo) |
Danvatirsen (50 mg/kg,s.c.,每周 5 天,持续 4 周) 可显著降低人 MDS/AML 细胞在 NSG 小鼠中的植入率。 Danvatirsen (100 mg/kg;s.c.;每周 5 次;持续 3 周) 联合 Cisplatin 可使神经母细胞瘤异种移植物的生长抑制率最高达 38%,并显著延长荷瘤小鼠的生存期。 Danvatirsen (25-50 mg/kg;s.c.;每周 5 次;持续 3 周) 可在人表皮样癌 A431 异种移植瘤中实现强效、剂量依赖性的 STAT3 mRNA 及蛋白耗竭,其中 25 mg/kg 剂量可使肿瘤 STAT3 mRNA 水平降低 90%。 Danvatirsen (50 mg/kg,s.c.,每周 5 次,持续 5 周) 可抑制人淋巴瘤 SUP-M2 异种移植物的生长,抑制率达 62%,并使肿瘤 STAT3 mRNA 水平降低约 40%,在播散性 SUP-M2 模型中表现出全身性抗淋巴瘤活性,可使肿瘤 STAT3 mRNA 降低约 50%,并降低血浆 sIL-2Rα 和 sCD30 的浓度。 Danvatirsen (25 mg/kg;s.c.;每周 5 次;约 5 周) 可将 PC-9 人非小细胞肺癌异种移植物的生长抑制 90%,并降低 STAT3 活性及下游靶基因的表达。
| Animal Model: |
Nonobese Diabetic Scid Gamma (NSG) (irradiated, engrafted with primary human MDS/AML peripheral blood mononuclear cells) |
| Dosage: |
50 mg/kg |
| Administration: |
s.c.; 5 days per week; 4 weeks |
| Result: |
Reduced MDS/AML burden, with greatly decreased fold change of human CD45+ cells in bone marrow compared with controls. Achieved complete loss of detectable human CD45+ cells in some treated mice. Exerted effects in both low-risk and high-risk MDS patient-derived xenografts. |
| Animal Model: |
athymic nude mice (5-6 week-old female) |
| Dosage: |
100 mg/kg (target reagent); 2 mg/kg (Cisplatin) |
| Administration: |
subcutaneous (target reagent; 5 times per week; 3 weeks); intraperitoneal (cisplatin; 2 times per week; 3 weeks; co-administered starting on day 11 of target reagent treatment) |
| Result: |
Reduced neuroblastoma xenograft growth by up to 38% compared to control-treated mice. Prolonged survival significantly compared to control-treated mice. |
| Animal Model: |
Immunocompromised mice; NSG mice (disseminated lymphoma model) |
| Dosage: |
25 mg/kg; 37.5 mg/kg; 50 mg/kg |
| Administration: |
5 times per week; 3 weeks (25 mg/kg, 50 mg/kg) |
| Result: |
Reduced tumor STAT3 mRNA by approximately 90% (P=0.0001) and STAT3 protein by 93% (25 mg/kg). Produced near-complete depletion of STAT3 protein throughout the tumor as measured by immunohistochemistry (50 mg/kg). |
| Animal Model: |
NSG mice, Immunocompromised mice |
| Dosage: |
50 mg/kg |
| Administration: |
5 times per week; 2, 5 weeks |
| Result: |
Reduced STAT3 mRNA by ~50% in tumors isolated from axillary lymph nodes and peritoneal cavity vs control groups. Reduced plasma sIL-2Rα and sCD30 concentrations. Reduced tumor burden (and ascites formation. Achieved 67% tumor growth inhibition (TGI). Confirmed inhibition of human STAT3 in tumor cells and murine STAT3 in tumor-associated stromal cells via species-specific PCR. Confirmed reduced phospho-STAT3 protein in both human tumor and mouse stromal cells via immunohistochemistry. No associated change in body weight was observed.
|
| Animal Model: |
Immunocompromised mice |
| Dosage: |
25 mg/kg |
| Administration: |
5 times per week; ~5 weeks |
| Result: |
Achieved 90% tumor growth inhibition (TGI) vs control. Reduced tumor STAT3 and phospho-STAT3 protein, and reduced expression of STAT3 target genes c-MYC, MCL-1, and VEGF. |
|